Fluifort gran. prigot. suspension d / int. reception 2.7 g / 5 g pack. �10

Release form, composition and packaging

Granules for preparation of oral suspension from white to light yellow

the prepared suspension is matte, light yellow, with a citrus scent.

1 pack.

carbocysteine ​​lysine salt monohydrate 2.7 g

citric acid - 0.08 g, mannitol - 0.9185 g, povidone - 0.1 g, natural cedrose flavoring - 0.04 g, natural orange flavoring - 0.04 g, orange juice (powder) - 0.296 g, aspartame - 0.03 g, maltodextrin - 0.7955 g.

5 g - sachets (10) - cardboard packs.

pharmachologic effect

Mucolytic agent.

It destroys the disulfide bonds of mucopolysaccharide and changes the charge of its ions, as a result of this, the composition of the bronchial secretion changes: the amount of neutral glycopeptides decreases, the sialoglycoprotein function increases.

Stimulates the motor function of the ciliated epithelium of the respiratory tract, reduces viscosity and facilitates the passage of bronchial secretions and discharge from the sinus sinuses.

Indications for use

Diseases of the respiratory system, accompanied by the release of a large amount of viscous mucus: acute and chronic bronchitis, tracheobronchitis, bronchitis with broncho-obstructive syndrome, bronchial asthma, whooping cough, bronchiectasis

inflammatory diseases of the middle ear and sinuses

preparation of the patient for bronchoscopy and / or bronchography.

Contraindications for use

Peptic ulcer and duodenal ulcer in the acute phase, chronic glomerulonephritis in the acute phase, I trimester of pregnancy, hypersensitivity to carbocysteine.

Dosage regimen

Adults when taken orally at the beginning of treatment - 750 mg 3 times / day

after achieving the clinical effect - 1.5 g / day in 3-4 doses.

Children aged 1 month to 2.5 years - 50 mg 2 times / day

at the age of 2.5 to 5 years - 100 mg 2 times / day

over 5 years old - 200-250 mg 3 times / day.

Side effect

From the digestive system: rarely - nausea, vomiting, epigastric pain, diarrhea, bleeding from the gastrointestinal tract.

Allergic reactions: rarely - skin rash, angioedema.

Application during pregnancy and lactation

Contraindicated for use in the first trimester of pregnancy.

Use with caution in the II and III trimesters of pregnancy and during lactation (breastfeeding).

special instructions

Use with caution in patients with a history of peptic ulcer disease.

Name ENG

FLUIFORT

Clinical and pharmacological group

Mucolytic drug

ATX code

Carbocisteine

Dosage

0.54g / g x 5g

Structure

1 sachet of granules for preparation of suspension for oral administration contains: active substance: carbocysteine ​​lysine salt monohydrate 2.7 g,

excipients: citric acid - 0.080 g

mannitol - 0.9185 g

PVP - 0.1 g

natural cedar flavor - 0.04 g

natural orange flavor - 0.04 g

orange juice powder - 0.2960 g

aspartame - 0.03 g

maltosextrin - 0.7955 g.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

INN / Active ingredient

Carbocisteine

Specifications

Category

Thinning phlegm

,

Expectorants

Scope of the drug

Respiratory system

Release form

Granules

Manufacturer country

Italy

Package quantity, pcs

ten

Minimum age from

16 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Dompe SPA

The amount of the dosage form in the primary package

5 g

Primary packaging type

Sachet (sachet)

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Expectorant mucolytic agent

Anatomical and therapeutic characteristics

R05CB03 Carbocisteine

Dosage form

Granules for preparation of oral suspension

The target audience

Children

Dosage (volume) of the substance in the preparation

carbocysteine ​​lysine salt monohydrate - 2.7 g

Expiration date in days

1095

Package weight, g

75

Mode of application

:

Adults: 1 sachet per day.

Dissolve the contents of the sachet in drinking water, stir. < br> The duration of treatment is determined by the doctor (from 4 days to 6 months).

The indicated dosage is the same for patients with impaired liver and kidney function, as well as for patients with diabetes.